Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 13/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.47 |
| ▸ | PDE4A | P27815 | 5/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13446206 | 0.94 | ADORA1 (0.46) | ADORA1ADORA2APDE4APDE4BPDE4C | |
| SCHEMBL7954497 | 0.93 | ADORA1 (0.45) | ADORA1ADORA2APDE4APDE4BPDE4C | |
| SCHEMBL13446201 | 0.89 | PDE4A (0.45) | ADORA1ADORA2APDE4APDE4BPDE4C | |
| SCHEMBL13446200 | 0.83 | PDE4A (0.47) | ADORA1ADORA2APDE4APDE4BPDE4C | |
| SCHEMBL7965578 | 0.83 | ADORA1 (0.46) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL13446204 | 0.82 | PDE4A (0.44) | ADORA1ADORA2APDE4APDE4BPDE4C | |
| SCHEMBL7952534 | 0.82 | ADORA2A (0.45) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL13446203 | 0.82 | ADORA2A (0.45) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL7959531 | 0.81 | ADORA1 (0.44) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL13446202 | 0.81 | ADORA1 (0.43) | ADORA1ADORA2AADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063071-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | BIOGEN IDEC MA INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100063071-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | BIOGEN IDEC MA INC. | 2010-03-11 | — | — | US | disclosed |
| EP-1347981-B1 | CONDENSED PURINE DERIVATIVES AS A 1 ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN IDEC INC (US) | 2008-05-07 | — | — | EP | disclosed |
| US-7022686-B2 | A1 adenosine receptro antagonists | BIOGEN IDEC INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030220358-A1 | A1 adenosine receptro antagonists | BIOGEN IDEC MA INC. | 2003-11-27 | — | — | US | disclosed |
| US-6605601-B2 | Hypotensive agents; cardiovascular disorders | BIOGEN, INC. | 2003-08-12 | — | — | US | disclosed |
| US-20020111333-A1 | A1 adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063071-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | ADORA2A, P2RX3, P2RX6 | ADORA1 8/4885ADORA2A 1/4885PDE4A 142/4885 |
| US-20030220358-A1 | A1 adenosine receptro antagonists | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885PDE4A 149/4885 |
| US-20020111333-A1 | A1 adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885PDE4A 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.